Investorideas.com

Get great ideas from our AI, cannabis, cleantech, crypto, esports and mining podcasts - be a guest or sponsor : 800 665 0411


Share on StockTwits

Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 424 (OTC: CSUI) (NASDAQ: GWPH) (CSE: PRMO) (TSX: ZENA)

 

Delta, Kelowna, BC - June 5, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/060520-StocksToWatch.mp3

Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 424 (OTC: CSUI) (NASDAQ: GWPH) (CSE: PRMO) (TSX: ZENA)

SHARE PODCAST:      

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

Today's podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

Today's podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI), a research & development company licensed under Swiss Cannabis and tobacco regulations to cultivate and sell cannabis. The Company's facilities for producing cannabis are based in Zurich.

The Company grows high quality, organic cannabis with sustainable, all-natural principles. Cannabis Suisse products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product.

In today's podcast we will be looking at a few public company announcements.

GW Pharmaceuticals plc (NASDAQ: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will host a virtual event for investors to provide a review of the U.S. development program and market opportunity for its late stage pipeline product, nabiximols. The program will be webcast live on June 30, 2020 from 10:00 am-12:00 pm EDT, and a replay will be available soon after the live presentation. Both the live webcast link and the archive will be available on GW's corporate website at www.gwpharm.com in the Investor section under

Justin Gover, GW's Chief Executive Officer, will host this event. The presentation will feature external medical and research experts as well as GW executives.

Nabiximols is expected to enter pivotal Phase 3 development in the United States in the second half of 2020. The U.S. commercial rights are owned by GW. GW anticipates developing multiple indications for nabiximols with an initial focus on spasticity. The initial target indication in the U.S. will be for the treatment of MS spasticity, potentially to be followed by Spinal Cord Injury spasticity and Post Traumatic Stress Disorder, or PTSD.

Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids THC and CBD and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides. The product is administered as a mouth spray.

Nabiximols is known as Sativex® outside of the United States and is licensed and commercially available for the treatment of MS spasticity in numerous countries. The efficacy of Sativex for MS spasticity has been demonstrated in multiple positive pivotal trials conducted in Europe.

PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) announced that further to its letter of intent with World Agri-Minerals Ltd. ("WAM"), announced in the Company's news release dated June 4, 2020, Primo and WAM have conducted discussions relating to the development and production of a proprietary mineral blend specially designed for employment by psilocybin mushroom growers.

The Company has identified growing global interest in the potential medical applications of psilocybin and other psychedelic mushrooms. With world-wide interest in this burgeoning Agri-landscape, WAM is currently developing a new proprietary mineral blend focused on enhancing the production and quality of mushrooms and in particular psychedelic mushroom production. WAM claims that their current research and testing will result in benefits similar to those attained when using their already successful GENESIS 89 GOLD blend on Hemp and Cannabis production. With the new WAM proprietary mineral natural mushroom blend, a healthy more vibrant and 100% organic product can be grown more economically thereby allowing product cost savings for the consumers in addition to enabling growers to be more efficient and profitable. WAM claims that that GENESIS 89 GOLD can increase Hemp and Cannabis productivity anywhere from 15% to 35%. WAM believes that a new mushroom blend could provide similar if not greater production numbers for psilocybin and other mushroom varieties grown for medical applications.

According to the Psychedelic Science Review, the global market for conventional anti-depressants was valued at $13.7 billion in 2016 and is projected to grow to $15.9 billion by 2023.

Andy Jagpal, President of Primo Nutraceuticals commented, "We believe that Primo is especially well positioned to capitalize on the emerging 'shroom boom' Psilobycin and other varieties of mushrooms are quickly becoming a viable option for mental and physical health treatment. The market for investment opportunity is massive for a nutraceutical company like Primo which has demonstrated its ability to receive NPNs (Natural Product Number) from the Health Products and Food Branch of Health Canada for nutraceutical products."

Zenabis Global Inc. (TSX: ZENA) announced that it has assigned its binding term sheet with Farmako GmbH to its subsidiary company ZenPharm for the supply of European Union Good Manufacturing Practices certified medicinal cannabis and amended the terms to provide for a minimum volume guarantee. The Company is also pleased to announce the receipt of its sales license amendment for Zenabis Stellarton from Health Canada.

  • Zenabis has assigned its term sheet with Farmako, which was announced on April 29, 2019, to its Maltese-based European joint venture, ZenPharm.
  • ZenPharm is expected to process EU GMP compliant bulk from Zenabis to supply Farmako with a minimum of 500 kg per year for a term of three years.
  • This is subject to ZenPharm itself obtaining EU GMP certification, which is expected to occur in Q3, 2020.
  • Shipments to Farmako are expected to commence in Q4, 2020.
  • ZenPharm anticipates supplying cannabis oils to Farmako beginning in 2021.

Kevin Coft, Chief Executive Officer of Zenabis, stated, "The assignment of this term sheet, and addition of minimum volumes, reinforces Zenabis' impetus for its international medicinal cannabis activities, in particular in Europe. Working with key distributors like Farmako is vital in ensuring patient accessibility to medicinal cannabis products in a manner that safeguards quality and consistency of supply. Zenabis anticipates significantly increasing supply to Europe from Q4 2020 onward, where bulk pricing of cannabis is now significantly more attractive than in the Canadian market."

Katrin Eckmans, Farmako Chief Executive Officer, stated, "Having visited Zenabis' Canadian facility at the end of 2019, I was very impressed. We have visited many facilities, and Zenabis' ability to maintain the highest standards of professionalism and quality throughout the organization even while operating on a massive scale is commendable. Zenabis' professional approach to growing cannabis, combined with Natrix Sciences' experience with innovative and complex pharmaceutical products in Malta is a perfect interplay to provide a broad portfolio of high quality medical cannabis products for patients in Germany and across Europe."

Angele Azzopardi, Chief Executive Officer ZenPharm said, "Our Team is incredibly proud to carry this operation forward. This agreement not only showcases Zenabis' commitment but also evidences the Zenabis, ZenPharm trans-Atlantic synergy in delivering medicinal cannabis products to Europe. We look forward to developing our relationship with Farmako, especially as more conventional dosage forms of medicinal cannabis products come to the market."

Hightimes Holding Corp., the owner of High Times®, the most well-known brand in cannabis, today announces that it has entered into a series of agreements with Red, White & Bloom, Inc. with the goal of the branding of High Times dispensaries and development of cannabis based CBD and THC products in the States of Michigan, Illinois and Florida.

RWB and its investee will use the Hightimes™ trademark, logo and brand to rebrand its 18 planned and operational dispensaries as High Times stores. Together, such stores represent more than 20% of the cannabis market share across the state. RWB'S Investee is the leading cannabis company in Michigan, with dispensaries, indoor/outdoor cultivation and product manufacturing established over the last two years. In addition, as a result of the acquisition of Newco, RWB will also acquire the rights to brand retail and medical dispensaries and products, in the states of Illinois and Florida, and may utilize RWB's massive 3.6 million square foot facility in Illinois for the production of proprietary branded CBD products and whole hemp flower strains for distribution nationally.

In addition to transforming the dispensaries to become High Times branded destinations and launching delivery capabilities in select locations, High Times branded products including vapes, tinctures, topicals, and edibles will be available within both owned dispensaries and other 3rd party outlets. The company has aggressive growth plans and is entering the market at a time when the retail landscape has been significantly changed.

"High Times is a 46-year-old brand with an immense amount of recognition and credibility across the world," said Peter Horvath, Chief Executive Officer of Hightimes Holding Corp. "Licensing the High Times name, advising on dispensary operations, and providing input on product development allows the company to drive significant revenue from licensing fees without assuming the complexity associated with owning and operating dispensaries and scaled cultivation and manufacturing facilities nationwide. RWB has built an incredible and expansive retail footprint in a quick time frame that we can strengthen through applying the High Times Brand."

The Hightimes subsidiary holding the Hightimes™ trademark, logo and brand worldwide, sublicensed such intellectual property to a newly formed special purpose Hightimes subsidiary for the purpose of using and branding retail and medical dispensaries and products in the State of Michigan and, subject certain regulatory approvals, in the States of Illinois and Florida as well. Under the terms of the agreement, the Hightimes Licensing Company sold to RWB 100% of the equity of Newco. In consideration for the sale, the Hightimes Licensing Company will receive $15,000,000 of RWB common shares which are expected to trade on the Canadian Securities Exchange and, subject to certain conditions, may receive an additional $5,000,000 of RWB common shares in the future. In addition to the share consideration, the Hightimes Licensing Company expects certain Minimum Guarantee payments during the term of the agreement and any renewal period.

Hightimes Holding Corp. has recently made several announcements ahead of the closing of its Regulation A+ IPO, including the appointment of CEO Peter Horvath and its proposed entry into retail cannabis dispensaries with the planned acquisition of 13 California dispensaries from Harvest Health & Recreation, one of the largest multi-state operators in cannabis. Through these and other strategic transactions, High Times intends to become one of the largest cannabis companies in California, and is working quickly to do the same in Michigan, Illinois and Florida.

Once again, today's podcast was sponsored by Cannabis Suisse Corp. (OTC: CSUI), a research & development company licensed under Swiss Cannabis and tobacco regulations to cultivate and sell cannabis. The Company's facilities for producing cannabis are based in Zurich.

The Company grows high quality, organic cannabis with sustainable, all-natural principles. Cannabis Suisse products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

Disclosure CSUI is a paid monthly news and social media cannabis stock

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Follow us on Cannabis Social Media

https://www.facebook.com/Investorideaspotcasts/

https://twitter.com/MJInvestorIdeas

https://www.instagram.com/investorideas_potcast/

Download our Mobile App for iPhone and Android

Contact Investorideas.com

800-665-0411


Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories

Buy a cannabis guest post on Investorideas.com